Munich Startup
brainboost GmbH

brainboost GmbH

brainboost is fully focused on the topic of mental fitness & health. With the help of neuro-technology, the Munich-based startup aims to counteract negative stigma surrounding mental illnesses and act preventatively in various...

Founded2026
Business Model-
IndustryBioTech
This content was machine translated.

About brainboost GmbH

brainboost is fully focused on the topic of mental fitness & health. With the help of neuro-technology, the Munich-based startup aims to counteract negative stigma surrounding mental illnesses and act preventatively in various areas of everyday life. Behind brainboost is an interdisciplinary team consisting of a doctor, sports and health scientists, business economists, psychologists, as well as software developers and data scientists. The company offers “brain training” to boost performance in the non-medical field using neurofeedback, creates so-called BrainMaps to determine a kind of “status quo” of the brain, as well as many other offerings to increase mental health. In addition, brainboost is active in the field of occupational health promotion and supports companies, for example, in conducting health days through lectures, events, and workshops. As experts in the field of mental fitness & health, the company has also developed its own software in the area of neurofeedback and trains interested parties to create a larger network and greater reach. Moreover, brainboost participates in various (government-funded) research projects in cooperation with diverse universities and colleges, and is thus always up to date with the latest developments.

More like this

Discover relevant articles, startups, and events from the ecosystem

EpiCure

EpiCure is a research project of Ludwig Maximilians University Munich and is scheduled to be incorporated as an independent biotech company in 2026/2027. The focus is on epigenetic therapies, a mechanism of action that still holds considerable untapped potential in oncology. The lead compound is Carbacitabin (CAB), a drug molecule rationally designed on the basis of epigenetic expertise for blood cancer diseases, primarily positioned for high-risk patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CAB was specifically developed to address the weaknesses of clinically used standard therapeutics, and achieves approximately 100-fold reduced toxicity in patient-derived tumor models while simultaneously demonstrating superior efficacy. The regulatory foundation is in place: The BfArM has confirmed the preclinical development program in Scientific Advice. The first clinical trial is planned for 2027/28.

B2BBioTech

2026Founded
-Team size
Seed stage

ProviGenAI

ProviGenAI develops a software platform for automated experiments and data-driven process optimization. Many laboratories and biotechnology development environments already have extensive automation in place, yet the planning, evaluation, and adaptation of experiments continues to be done manually. Our platform combines automated laboratory workflows with AI-based optimization. It translates experimental protocols into executable workflows, orchestrates experiments on existing automation systems, and analyzes the resulting data to continuously improve parameters. This creates closed learning loops between experiment, analysis, and decision-making. Teams can optimize biotechnological processes—such as fermentation, screening, or bioprocess development—significantly faster and more efficiently.

B2BBioTech

2026Founded
-Team size
Seed stage